A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

被引：19
|
作者：
Cortes, Jorge E. [1 ]
Heidel, Florian H. [2 ,3 ]
Heuser, Michael [4 ]
Fiedler, Walter [5 ,6 ]
Smith, B. Douglas [7 ]
Robak, Tadeusz [8 ,9 ]
Fernandez, Pau Montesinos [10 ]
Ma, Weidong Wendy [11 ]
Shaik, M. Naveed [12 ]
Zeremski, Mirjana [12 ]
O'Connell, Ashleigh [13 ]
Chan, Geoffrey [13 ]
机构：
[1] Univ Texas M Anderson Canc Ctr, Houston, TX USA
[2] Otto Guericke Univ Med Ctr, Dept Hematol, Ctr Internal Med, Magdeburg, Germany
[3] Otto Guericke Univ Med Ctr, Dept Oncol, Ctr Internal Med, Magdeburg, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Oncol, Hamburg, Germany
[6] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol, Hamburg, Germany
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Med Univ Lodz, Dept Hematol, Lodz, Poland
[9] Copernicus Mem Hosp, Lodz, Poland
[10] Hosp Univ Fe, Valencia, Spain
[11] Pfizer Oncol, New York, NY USA
[12] Pfizer Oncol, La Jolla, CA USA
[13] Pfizer Oncol, Collegeville, PA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.99.99
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
    Cortes, J. E.
    Smith, B. D.
    Wang, E. S.
    Merchant, A.
    Oehler, V. G.
    Arellano, M.
    DeAngelo, D. J.
    Pollyea, D. A.
    Ma, W. W.
    Zeremski, M.
    Shaik, M. N.
    O'Connell, A.
    Chan, G.
    Schroeder, M. A.
    HAEMATOLOGICA, 2017, 102 : 50 - 50
  • [2] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [3] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
  • [4] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Jorge E. Cortes
    Florian H. Heidel
    Andrzej Hellmann
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Daniel A. Pollyea
    Pierre DesJardins
    Oliver Ottmann
    Weidong Wendy Ma
    M. Naveed Shaik
    A. Douglas Laird
    Mirjana Zeremski
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Leukemia, 2019, 33 : 379 - 389
  • [5] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Cortes, J.
    O'Connell, A.
    Shaik, M. N.
    Cesari, R.
    Abbattista, A.
    Woolfson, A.
    Pollyea, D.
    Savona, M.
    HAEMATOLOGICA, 2014, 99 : 33 - 33
  • [6] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
    Dennis, Mike
    Thomas, Ian F.
    Ariti, Cono
    Upton, Laura
    Burnett, Alan K.
    Gilkes, Amanda
    Radia, Rohini
    Hemmaway, Claire
    Mehta, Priyanka
    Knapper, Steven
    Clark, Richard E.
    Copland, Mhairi
    Russell, Nigel
    Hills, Robert K.
    BLOOD ADVANCES, 2021, 5 (24) : 5621 - 5625
  • [8] Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes
    Izutsu, Koji
    Ubukawa, Kumi
    Morishita, Takanobu
    Onishi, Yasushi
    Ishizawa, Kenichi
    Fujii, Yosuke
    Kimura, Nobuyuki
    Yokochi, Miyuu
    Naoe, Tomoki
    CANCER SCIENCE, 2024, 115 (04) : 1250 - 1260
  • [9] Phase I evaluation of tipifarnib in combination with low dose Ara-C (LDAC) in high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): final results
    Feldman, E. J.
    Douer, D.
    Walsh, W.
    Moyo, V. M.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Idarubicin, ara-c, and topotecan in patients with refractory or relapased acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Min, YH
    Jang, JH
    Lee, ST
    Hahn, JS
    Ko, YW
    BLOOD, 1999, 94 (10) : 234B - 234B
12345